• Among the conditions HSCT can treat are: acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, non-Hodgkin lymphoma, Hodgkin disease, aplastic anemia and pure red-cell aplasia-but this list is not exhaustive. (drugdiscoverynews.com)
  • Myelodysplastic syndromes were the most prevalent subgroup (IR = 1.7, 95% CI 1.5-1.8). (bvsalud.org)
  • Incidence of all myeloid malignancies combined increased sharply during the study period with an annual percent change (APC) of 10.06% (95% CI 9.51-10.61), 19.77% for myelodysplastic syndromes (95% CI 19.63-19.91), and 3.18% (95% CI 2.99-3.37) for acute myeloid leukemia. (bvsalud.org)
  • Other types of bone marrow abnormalities, such as myeloproliferative disorder, a disease in which bone marrow cells multiply outside of the bone marrow tissue, or myelodysplastic ('preleukemia') syndromes, are the result of marrow dysfunction in either the stem cells or progenitor cell lines. (dwib.org)
  • The incidence rate of the myelodysplastic syndromes (MDS) in the United States is approximately 3.4 per 100,000 people, accounting for more than 10,000 new diagnoses annually and an estimated 60,000 people living with the disease. (jnccn.org)
  • T he first description of patients with a blood picture compatible with the myelodysplastic syndromes (MDS) was published at the beginning of the 20th century, 1 and the first MDS case series was published in the early 1970s. (jnccn.org)
  • Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid neoplasms characterized by the presentation of overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. (encyclopedia.pub)
  • Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) constitute a heterogeneous group of clonal myeloid malignancies with clinical, laboratory, morphologic and genetic features that overlap with myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). (encyclopedia.pub)
  • Spliceosome mutations are common in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), but the oncogenic changes due to these mutations have not been identified. (cancer-genetics.org)
  • 8. Which of the following genetic abnormalities is commonly associated with myelodysplastic syndromes (MDS)? (medicalbiochemist.com)
  • MDS is related to another group of conditions called myeloproliferative neoplasms (MPNs). (myleukemiateam.com)
  • For patient education information, see Myelodysplastic or Myeloproliferative Neoplasms (Leukemia Types). (medscape.com)
  • Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms" Encyclopedia , https://encyclopedia.pub/entry/10288 (accessed December 10, 2023). (encyclopedia.pub)
  • Although the classification of MDS/MPN relies largely on clinical features and peripheral blood and bone marrow morphology, studies have demonstrated that a large proportion of patients (~90%) with this disease harbor somatic mutations in a group of genes that are common across myeloid neoplasms. (encyclopedia.pub)
  • 10. Which of the following is a common finding in myeloproliferative neoplasms (MPNs)? (medicalbiochemist.com)
  • PDGFRβ gene rearrangements are infrequent entities, which are mostly diagnosed in patients presenting with atypical CML, chronic myelomonocytic leukemia (CMML), myelodysplastic/myeloproliferative disorders (MDS/MPN) or juvenile myelomonocytic leukemia (JMML). (fortunejournals.com)
  • Myelodysplastic syndrome (MDS) refers to a heterogeneous group of closely related clonal hematopoietic disorders commonly found in the aging population. (medscape.com)
  • Myeloproliferative diseases are a heterogeneous group of disorders characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. (medscape.com)
  • Cytogenetic studies detect the presence or absence of the Philadelphia chromosome and help to differentiate myeloproliferative disorders from myelodysplastic syndrome. (medscape.com)
  • Myelodysplastic Syndrome (MDS) The myelodysplastic syndrome (MDS) is group of clonal hematopoietic stem cell disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a hypercellular or hypocellular. (msdmanuals.com)
  • Platelet disorders lead to defects in primary hemostasis and produce signs and symptoms different from coagulation factor deficiencies (disorders of secondary hemostasis). (medscape.com)
  • These are a group of disorders characterized by abnormal growth and development of cells in the myeloid lineage, which includes granulocytes, monocytes erythrocytes, platelets, etc. (medicalbiochemist.com)
  • Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. (wikipedia.org)
  • What Is Myelodysplastic Syndrome (MDS)? (myleukemiateam.com)
  • Myelodysplastic syndrome (MDS) is a form of a precancerous blood condition . (myleukemiateam.com)
  • How Does Myelodysplastic Syndrome Develop? (myleukemiateam.com)
  • Myelodysplastic syndrome derives part of its name from the word "dysplastic," which refers to abnormal cell development or growth. (myleukemiateam.com)
  • Who Gets Myelodysplastic Syndrome? (myleukemiateam.com)
  • For discussion of MDS in children, see Pediatric Myelodysplastic Syndrome. (medscape.com)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • We investigated the time trend of acute myeloid leukemia (N = 1227 cases), chronic myeloid leukemia (N = 613 cases), and myelodysplastic syndrome (N = 1296 cases), and used Bayesian methods to explore their geographic spread, and Poisson regression analysis to estimate their association with environmental and socio-economic factors. (bvsalud.org)
  • Several published literatures revealed that some oncogenes, such as MYC and MLL, have been identified to be amplified on dmins in AML and myelodysplastic syndrome (MDS) [ 6 ]. (hindawi.com)
  • Hypereosinophilic syndrome (HES) is a myeloproliferative disorder (MPD) characterized by persistent eosinophilia that is associated with damage to multiple organs. (medscape.com)
  • Toxic shock like syndrome caused by Streptococcus agalactiae bacteremia during treatment for multiple myeloma. (u-tokyo-hemat.com)
  • Imatinib Mesylate tablets can be used for multiple indications including Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hyper eosinophilic syndrome (HES) and aggressive systemic mastocytosis (ASM). (researchandmarkets.com)
  • Ear drops?AutoPap: Computer-assisted cytology interpretation system?AV: Aortic valve?AV: Atrioventricular?A-V: Arteriovenous?AVERT: Atorvastatin Versus Revascularization treatment?AVID: ?AVM: Arteriovenous Malformation?AVNRT: AV nodal reentry tachycardia?AVP: Arginine vasopressin?AVR: Aortic valve replacement?AVR: Augmented V lead, right arm (ECG)?AVRT: ?AVS: Arteriovenous shunt?AWS: Alcohol withdrawal syndrome?AXR: Abdominal X ray?AZF: Azoospermia factor genes?AZT: Azidothymidine (zidovudine)?B & O: Belladonna and opium?B Bx. (kuwaitpharmacy.com)
  • Instead, it is a chronic therapy that helps to control the disease and prevent it from progressing. (wikipedia.org)
  • Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. (tajgenerics.com)
  • Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy. (theindianpharma.com)
  • Rearrangements in the platelet-derived growth factor receptor β (PDGFRβ) gene result in greater constitutive enzymatic activity (tyrosine kinase) and deregulation of haematopoiesis, similarly to BCR-ABL1 in chronic myeloidleukemia (CML). (fortunejournals.com)
  • Dasatinib (Sprycel): Indicated for the treatment of adult patients with chronic myeloid leukemia in chronic, accelerated, or myeloid or lymphoid blast phase who are resistant or intolerant to prior therapy including imatinib. (medscape.com)
  • Primary Myelofibrosis Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, and anemia with nucleated and teardrop-shaped red blood cells. (msdmanuals.com)
  • Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis. (u-tokyo-hemat.com)
  • Cervical vertebrae 1,2, …?Ca: Calcium?Ca: Cancer?Ca: Carcinoma?Ca: Cardiac arrest?Ca: Coronary artery?CA-125: A tumor marker for ovarian cancer?CAB: Cellulose acetate butyrate?CABG: Coronary artery bypass graft?CACI: Computer-Assisted Continuous Infusion?CAD: Coronary artery disease?CAG: ?CAH: Chronic active hepatitis?CAH: Congenital adrenal hyperplasia?calid. (kuwaitpharmacy.com)
  • It is also an specific inhibitor of the receptor tyrosine kinases for the PDGF (platelet-derived growth factor) and stem cell factor (SCF), c-kit, and inhibits PDGF- and cellular events of SCF-mediated. (theindianpharma.com)
  • The drug targets KIT and PDGFRA (platelet-derived growth factor receptor A) proteins blocking the growth of tumor cells. (researchandmarkets.com)
  • MDS is called treatment-related or secondary MDS when it occurs in someone who has previously had cancer treatment or has been diagnosed with another blood disorder. (myleukemiateam.com)
  • They are also at risk of developing secondary acute leukemia from their underlying disorder, as well as from their treatment. (medscape.com)
  • Acute myeloid leukemia in a child with familial platelet disorder and a cryptic runx1 intragenic deletion. (atlasgeneticsoncology.org)
  • Beyond Pathogenic RUNX1 Germline Variants: The Spectrum of Somatic Alterations in RUNX1-Familial Platelet Disorder with Predisposition to Hematologic Malignancies. (atlasgeneticsoncology.org)
  • Peptic ulcer disease can also be due to Helicobacter pylori infection, the incidence of which is increased in PV, while the pruritus associated with this disorder may be a consequence of mast cell activation by JAK2 V617F. (basicmedicalkey.com)
  • It is also not prescribed by the doctor if you have ever suffered with low blood platelets level, swelling, low white blood cells, bone marrow, pulmonary fibrosis, etc. (theindianpharma.com)
  • Veenat 400mg(Imatinib 400mg) is a antineoplastic agents and used by alone regimen or together with other medicines for the treatment of different types of cancer or bone marrow conditions, the main ingredient which is used as Imatinib. (myapplepharma.com)
  • The platelets arise from the fragmentation of the cytoplasm of megakaryocytes in the bone marrow and circulate in blood as disc-shaped anucleate particles for 7-10 days. (medscape.com)
  • Early recognition and treatment are crucial since a proportion of patients develop severe complications, such as bone marrow failure and irreversible neurological impairment. (mjhid.org)
  • Sargramostim is a colony stimulating factor that is FDA approved for the treatment of granulocytopenia following induction chemotherapy in acute myelogenous leukemia , mobilization and following transplantation of autologous peripheral blood progentior cells, myeloid reconstitution after autologous bone marrow transplantation, myeloid reconstitution after allogeneic bone marrow transplantation and bone marrow transplantation failure or engraftment delay. (wikidoc.org)
  • The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause. (lookformedical.com)
  • The current treatment for incomplete hematopoietic recovery includes administration of factors stimulating white and red blood cell growth, such as granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin. (drugdiscoverynews.com)
  • PLX-R18 cells, derived from mesenchymal-like cells collected from donated placentas, are designed to release a combination of therapeutic proteins to jumpstart the regeneration of a poorly functioning hematopoietic system. (drugdiscoverynews.com)
  • They are derived from hematopoietic cells called stem cells. (dwib.org)
  • This phenomenon occurs in otherwise unmanipulated murine marrow in vivo, resulting in circulating platelets that bear membrane from non-megakaryocytic hematopoietic donors. (elifesciences.org)
  • Similarly, no specific cytogenetic abnormality is associated with the disease, and the absence of a cytogenetic marker does not exclude the diagnosis. (basicmedicalkey.com)
  • Median age at diagnosis is 72 years and it is an infrequent disease in young adults [ 6 ] [ 7 ] . (encyclopedia.pub)
  • Treatment of AML begins with establishing a precise diagnosis. (ashpublications.org)
  • Veenat 400mg(Imatinib 400mg) also prevent receptor kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, PDGF- and SCF-mediated cellular effects. (myapplepharma.com)
  • Some patients may need to continue taking Imatinib for an extended period of time to maintain remission, and some patients may eventually require additional treatment options. (wikipedia.org)
  • The FDA granted approval for the treatment of dermatofibrosarcoma protuberans (DFSP) patients in 2006. (wikipedia.org)
  • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test. (hikma.com)
  • The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. (tajgenerics.com)
  • In the Vivo, imatinib inhibits the growth of tumor of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from the CML patients in the blast crisis. (theindianpharma.com)
  • These patients have a worse prognosis and response to treatment. (medscape.com)
  • Patients who survive cancer treatment with alkylating agents, with or without radiotherapy, have a high risk of developing MDS or secondary acute leukemia 5-7 years after the exposure. (medscape.com)
  • Thus, there is an unmet need for additional treatment options for these patients. (drugdiscoverynews.com)
  • this is the treatment of choice for most patients. (medscape.com)
  • Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (blogspot.com)
  • Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (blogspot.com)
  • for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. (blogspot.com)
  • Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (blogspot.com)
  • Erythropoiesis stimulating agents are used by more than 50% of patients, although the use of disease-modifying agents is increasing, and may ultimately have an impact on the number of patients living with MDS. (jnccn.org)
  • As one would expect of a disease primarily affecting older adults, incidence rates were lowest for people younger than 40 years, at 0.14 per 100,000, and highest with increasing age, reaching a level of 36 per 100,000 for patients aged 80 years and older. (jnccn.org)
  • Of course, in patients with associated acid-peptic disease, occult gastrointestinal bleeding may lead to a presentation with hypochromic, microcytic anemia, masking the presence of PV. (basicmedicalkey.com)
  • Dr. Tallman focuses on the molecular genetics of APL, current curative treatment strategies and approaches for patients with relapsed and refractory disease. (ashpublications.org)
  • These mutations play a role in the clinical heterogeneity of these diseases and their clinical evolution. (encyclopedia.pub)
  • Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
  • Imatinib is considered to be a very effective treatment for CML, and has been shown to improve outcomes for people with this type of leukemia. (wikipedia.org)
  • It's important to note that while Imatinib is a very effective treatment for CML and some types of ALL, it is not a cure for leukemia. (wikipedia.org)
  • As the disease progresses and converts into leukemia, further gene mutation occurs, and a proliferation of leukemic cells overwhelms the healthy marrow. (medscape.com)
  • Role of signal transduction inhibition in treatment of acute myelogenous leukemia/myelodysplasia. (rochester.edu)
  • Monitoring minimal residual disease in RUNX1-mutated acute myeloid leukemia. (atlasgeneticsoncology.org)
  • Acute myeloid leukemia (AML) is mainly a fatal disease. (biomedcentral.com)
  • The term acute myeloid leukemia (AML) collectively refers to a mixture of distinct diseases that differ with regard to their pathogenetic evolution, genetic abnormalities, clinical features, response to therapy, and prognosis. (ashpublications.org)
  • The U.S. Food and Drug Administration (FDA) has approved imatinib as first-line treatment for Philadelphia chromosome-positive CML, both in adults and children. (wikipedia.org)
  • For treatment of progressive plexiform neurofibromas associated with neurofibromatosis type I, early research has shown potential for using the c-KIT tyrosine kinase blocking properties of imatinib. (wikipedia.org)
  • Complete remission (CR) was achieved and imatinib was used as maintenance treatment. (fortunejournals.com)
  • Both of the men and women: avoid conceive a child (get pregnant) while on treatment with Veenat 400mg(Imatinib 400mg) . (myapplepharma.com)
  • The initial hemostatic plug, composed primarily of platelets, is stabilized further by a fibrin mesh generated in secondary hemostasis. (medscape.com)
  • The peripheral smear below shows leukoerythroblastosis and giant platelets in a patient with myelofibrosis. (medscape.com)
  • Myelofibrosis appears to be part of the natural history of the disease but is a reactive, reversible process that does not itself impede hematopoiesis and by itself has no prognostic significance. (basicmedicalkey.com)
  • Also known as progenitor cells, unipotential cells become committed to forming only one type of blood cell line - erythrocytes (red blood cells), leukocytes (white blood cells), or platelets. (dwib.org)
  • Depending on which progenitor cells cease to work, the person may develop pure red cell aplasia (lack of red blood cells), megakaryocytic aplasia (absence of platelets) or leukopenia (low white blood cell count). (dwib.org)
  • Macrophages derived from blood monocytes and resident macrophages produced during embryonic development can be activated to amplify control of infection, but they can also produce substances that induce unwanted excessive inflammation. (msdmanuals.com)
  • The number of blood cells produced every day is enormous: in the normal adult, production amounts to about 2.5 billion erythrocytes, 2.5 billion platelets, and 1.0 billion granulocytes (granular leukocytes) per kilogram of body weight. (dwib.org)
  • Under physiological circumstances, the resistance of the endothelial cell lining to interactions with platelets and coagulation factors prevents thrombosis. (medscape.com)
  • Neither phlebotomy nor iron deficiency increases the platelet count relative to the effect of the disease itself, and thrombocytosis is not correlated with thrombosis in PV, in contrast to the strong correlation between erythrocytosis and thrombosis in this disease. (basicmedicalkey.com)
  • Their ongoing Phase 2 study is evaluating whether infusion of mesenchymal stem cells (MSCs) can treat steroid-resistant acute graft-versus-host disease (GVHD) or poor graft function after HSCT. (drugdiscoverynews.com)
  • Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. (unicatt.it)
  • Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. (u-tokyo-hemat.com)
  • Hodgkin disease. (lookformedical.com)
  • Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE. (lookformedical.com)
  • The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. (lookformedical.com)
  • In 2006 the FDA expanded approved use to include dermatofibrosarcoma protuberans (DFSP), myelodysplastic/myeloproliferative diseases (MDS/MPD), and aggressive systemic mastocytosis (ASM). (wikipedia.org)
  • Once activated, platelets have two major mechanisms to recruit additional platelets to the growing hemostatic plug. (medscape.com)
  • This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as the influx of investigational approaches and novel drugs into the pipeline of clinical trials that target pathogenetic mechanisms of the disease. (ashpublications.org)
  • Funding encompasses a broad spectrum of hematologic inquiry, ranging from stem cell biology to medical management of blood diseases and to assuring the adequacy and safety of the nation's blood supply. (hhs.gov)
  • One trial is testing whether MSCs with or without peripheral blood stem cells could treat poor graft function and delayed platelet engraftment. (drugdiscoverynews.com)
  • Centers for Disease Control and Prevention. (cdc.gov)
  • 1 With some variations, most centers apply treatment schedules based on these drugs, sometimes supplemented with etoposide. (ashpublications.org)
  • In addition, when platelets are activated, negatively charged phospholipids move from the inner to the outer leaflet of the membrane bilayer. (medscape.com)
  • Moreover, it causes a reduction of the methionine-derived metabolite S-adenosylmethionine (SAM), required for neurotransmitters and phospholipids synthesis, eventually compromising cell membrane structure and fluidity, myelin formation, and neurotransmission. (mjhid.org)
  • Incomplete engraftment (poor graft function) requires the patient to undergo more transfusions of red cells or platelets. (drugdiscoverynews.com)
  • Platelet activation allows binding of these proteins, which bridges adjacent platelets. (medscape.com)
  • The alpha granules contain hemostatic proteins such as fibrinogen, vWf, and growth factors (eg, platelet-derived growth factor and transforming growth factors). (medscape.com)
  • The mammalian genome comprises nuclear DNA (nDNA) derived from both parents and mitochondrial DNA (mtDNA) that is maternally inherited and encodes essential proteins required for oxidative phosphorylation. (regenerativemedicine.net)
  • The red pulp also serves as a reservoir for blood elements, especially white blood cells (WBCs) and platelets. (msdmanuals.com)
  • The adult spleen - which holds the largest collection of blood-filtering lymphatic tissue in the body - is roughly 5 inches long and weighs about 5 to 7 ounces, but these measurements vary greatly with age, nutrition, disease status, and other factors. (dwib.org)
  • The hemostatic system consists of platelets, coagulation factors, and the endothelial cells lining the blood vessels. (medscape.com)
  • Many of the clinical complications of PV relate directly to the increase in blood viscosity associated with red cell mass elevation and indirectly to the increased turnover of red cells, leukocytes, and platelets with the attendant increase in uric acid and cytokine production. (basicmedicalkey.com)
  • There are complications of serial transfusions of either of these cell types, and a patient needs intense prophylactic treatments to protect from infections if his or her white counts are low. (drugdiscoverynews.com)
  • Platelets contain two unique types of granules: alpha granules and dense granules. (medscape.com)
  • Cytogenetic and molecular analyses have been instrumental in identifying disease entities among the mixed bag of AML types. (ashpublications.org)
  • Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. (researchandmarkets.com)
  • Different approaches have been worked on to derive the market value and market growth rate. (researchandmarkets.com)
  • In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. (cdc.gov)
  • The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. (lookformedical.com)
  • These findings identify emperipolesis as a new cell-in-cell interaction that enables neutrophils and potentially other cells passing through the megakaryocyte cytoplasm to modulate the production and membrane content of platelets. (elifesciences.org)
  • A general term for various neoplastic diseases of the lymphoid tissue. (lookformedical.com)
  • Several groups are conducting trials to determine whether cellular therapy could be the treatment of choice for poor graft function after HSCT. (drugdiscoverynews.com)
  • Common risk factors for developing MDS include advanced age, male gender, and antecedent exposure to chemotherapy or radiation as treatment for other cancers, which alone accounts for 10% of MDS cases. (jnccn.org)
  • Intracytoplasmic neutrophils develop membrane contiguity with the demarcation membrane system, thereby transferring membrane to the megakaryocyte and to daughter platelets. (elifesciences.org)
  • Platelets play a primary role in this process, interacting with subendothelium-bound von Willebrand factor (vWf) via the membrane glycoprotein (GP) Ib complex. (medscape.com)
  • An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. (lookformedical.com)
  • Dr. Löwenberg describes upcoming possibilities for predicting prognosis in defined subsets by molecular markers and reviews experimental strategies to improve remission induction and postinduction treatment. (ashpublications.org)